Drug intelligence / Profile preview

52Mn(PC2ABnAM-EA-MAL-Cys-HER2)

Development stage
Preclinical
Lead developer
University of Debrecen
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration
Intravenous
01

Overview

52Mn(PC2ABnAM-EA-MAL-Cys-HER2) is a radiolabeled anti-HER2 affibody conjugate developed for positron emission tomography (PET) and magnetic resonance (MR) imaging of HER2-positive tumors. It consists of an anti-HER2 affibody (a small engineered scaffold protein with high affinity for HER2) conjugated via a cysteine residue to a pyclen-based bifunctional chelator (PC2ABnAM-EA-MAL) and labeled with the positron-emitting isotope manganese-52 (52Mn). The long half-life of 52Mn (5.59 days) makes it suitable for extended-time-point PET imaging. Preclinical studies in mouse models bearing HER2-positive xenografts have demonstrated its potential as a targeted molecular imaging probe, although it exhibits significant accumulation in the kidneys.

Other names
[52Mn(PC2ABnAM-EA-MAL-Cys-HER2)][52Mn]Mn-3,9-PC2ABnpMA-affibody52Mn-PC2ABnAM-EA-MAL-Cys-HER2
02

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on 52Mn(PC2ABnAM-EA-MAL-Cys-HER2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 52Mn(PC2ABnAM-EA-MAL-Cys-HER2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call